hzvsf-v13
mAbexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03653208)
Timeline
Indications
Mechanism of action
- VimentinINHIBITOR
VIM inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095111 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06306339 | Phase 2 | Mar 31, 2024 | ImmuneMed, Inc. |
| NCT04679350 | Phase 2 | Mar 18, 2021 | ImmuneMed, Inc., Linical Americas |
| NCT04679415 | Phase 2 | Dec 31, 2020 | ImmuneMed, Inc., PT. Prodia Diacro Laboratories, Rumah Sakit Umum Persahabatan |
| NCT04676971 | Phase 2 | Dec 11, 2020 | ImmuneMed, Inc., OPIS s.r.l |
| NCT04817202 | Phase 1 | Sep 16, 2020 | CMAX Clinical Research, ImmuneMed, Inc. |
| NCT03653208 | Phase 1 | Oct 31, 2018 | ImmuneMed, Inc., Seoul National University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneMed, Inc. | For profit | 6 | 6 | 2 | 2018 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2020 |
| Linical Americas | For profit | 1 | 0 | 1 | 2021 |
| OPIS s.r.l | For profit | 1 | 0 | 1 | 2020 |
| PT. Prodia Diacro Laboratories | For profit | 1 | 0 | 1 | 2020 |
| Rumah Sakit Umum Persahabatan | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2018 |
7 organizations
Page 1 / 1